跳至主要内容
临床试验/NCT02963363
NCT02963363终止不适用

Feasibility Study of an Adapted Physical Activity (APA) for Breast Cancer Patients Treated by Neoadjuvant Chemotherapy and Targeted Therapy Against HER2

Centre Jean Perrin2 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2018年4月27日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
36
试验地点
2
主要终点
Rate of patients reaching international physical activity recommendations for post-neoadjuvant chemotherapy assessment

研究概览

简要总结

The purpose of this study is to assess the feasibility of a home-based adapted physical activity during neoadjuvant chemotherapy for HER2+ breast cancer.

详细描述

After the assessment of their physical fitness, a home-based adapted physical activity program composed by aerobic and muscle strengthening exercises will be delivered to each patient. The aim of the intervention is to reach international recommendation in a progressive way during neoadjuvant chemotherapy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Women > 18 years old
  • Patient with HER2 (Human Epidermal growth factor Receptor 2) positive breast cancer histologically proven, eligible for neoadjuvant chemotherapy and targeted therapy against HER-2
  • Affiliation to the French social security scheme
  • Patient who signed the participation consent before entering the trial
  • Medical fitness certificate for sport

排除标准

  • Diagnosis of a second malignancy in the past 5 years, with the exception of a basal cell skin cancer
  • Metastatic cancer
  • Karnofsky index ≤ 90%
  • Pregnant women
  • Significant psychiatric or neurological abnormality
  • Patient deprived of liberty by a court or administrative
  • Contraindication for physical activity
  • Patient unable to complete questionnaires (language barrier)
  • Participation in a clinical trial with the same objective

结局指标

主要结局

Rate of patients reaching international physical activity recommendations for post-neoadjuvant chemotherapy assessment

时间窗: Change from baseline (T0: before neoadjuvant chemotherapy) at the 5 months (T1: end of neoadjuvant chemotherapy)

Time spent to physical activity and sedentariness will be evaluated by Recent Physical Activity Questionnaire (RPAQ)

次要结局

  • Physical capacity : VO2max(Before (T0) and at the end (T1 : + 5 months) of neoadjuvant chemotherapy + before (T2 : + 8 months) and at the end (T3 : 20 month) of targeted therapy)
  • Lipid profile : total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides(Before (T0) and at the end (T1 : + 5 months) of neoadjuvant chemotherapy + before (T2 : + 8 months) and at the end (T3 : 20 month) of targeted therapy)
  • Physical capacity : Voluntary muscular strength(Before (T0) and at the end (T1 : + 5 months) of neoadjuvant chemotherapy + before (T2 : + 8 months) and at the end (T3 : 20 month) of targeted therapy)
  • Ventricular ejection fraction assessed by echocardiography or cardiac scintigraphy(Before (T0) and at the end (T1 : + 5 months) of neoadjuvant chemotherapy + before (T2 : + 8 months) and at the end (T3 : 20 month) of targeted therapy)
  • Changes of cancer treatment(At each cycle of neoadjuvant chemotherapy : every three weeks during 5 months)
  • Quality of life : Quality of Life Questionnaire-C30(Before (T0) and at the end (T1 : + 5 months) of neoadjuvant chemotherapy + before (T2 : + 8 months) and at the end (T3 : 20 month) of targeted therapy)
  • Physical capacity : six-minutes walking distance test(Before (T0) and at the end (T1 : + 5 months) of neoadjuvant chemotherapy + before (T2 : + 8 months) and at the end (T3 : 20 month) of targeted therapy)
  • Assessment of physical activity level using a validated smartphone application (eMouveRecherche)(Before (T0) and at the end (T1 : + 5 months) of neoadjuvant chemotherapy + before (T2 : + 8 months) and at the end (T3 : 20 month) of targeted therapy)
  • Longitudinal evolution of RPAQ score(Before (T0) and at the end (T1 : + 5 months) of neoadjuvant chemotherapy + before (T2 : + 8 months) and at the end (T3 : 20 month) of targeted therapy)
  • Asthenia : Multidimensional Fatigue Inventory-20(Before (T0) and at the end (T1 : + 5 months) of neoadjuvant chemotherapy + before (T2 : + 8 months) and at the end (T3 : 20 month) of targeted therapy)
  • Anthropometrics measurements(Before (T0) and at the end (T1 : + 5 months) of neoadjuvant chemotherapy + before (T2 : + 8 months) and at the end (T3 : 20 month) of targeted therapy)

研究者

发起方
Centre Jean Perrin
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Adapted Physical Activity for Breast Cancer HER2... | 临床试验